Citation for published version:
Jevglevskis, M, Threadgill, MD, Woodman, TJ & Lloyd, MD 2014, 'A novel elimination reaction catalysed by human alpha-methylacyl-CoA racemase (AMACR; P504S) and potential applications for measuring enzyme activity' Oslo Prostate Cancer Symposium, University of Oslo, Norway, Oslo, Norway, 14/05/14 - 16/05/14.

Publication date:
2014

Link to publication

University of Bath

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
A NOVEL ELIMINATION REACTION CATALYSED BY HUMAN α-METHYLACYL-COA RACEMASE (AMACR; P504S), AND POTENTIAL APPLICATION FOR MEASURING ACTIVITY.

Maksims Yevglevskis, Michael D. Threadgill, Timothy J. Woodman, Matthew D. Lloyd
Medicinal Chemistry, Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom
Email: M.Jevglevskis@bath.ac.uk

Branched-chain 2-methyl fatty acids are derived from abundant dietary lipids and cholesterol. β-Oxidation of these lipids requires S-methyl groups, but those with R-methyl groups are common. α-Methylacyl-CoA racemase (AMACR; P504S) catalyses chiral inversion, enabling metabolism. The enzyme is also important for conversion of the R-enantiomers of ibuprofen and related drugs to their pharmacologically active S-enantiomers. The enzyme works by a deprotonation/reprotonation mechanism via an enolate intermediate.

AMACR protein levels and activity are increased in all prostate cancers. Reduction of levels using siRNA causes prostate cancer cells to revert to a more normal phenotype, including restoration of androgen dependent growth. The enzyme is therefore a promising new drug target. However, development of this target has been hampered by the difficulties in measuring chiral inversion and the resulting lack of a convenient, high-throughput assay. Consequently, only three studies on inhibitors of AMACR have been reported since 2001.

Incubation of novel substrates containing fluorine with active human recombinant AMACR 1A resulted in the formation of an unsaturated product. Negative controls containing inactive enzyme did not produce a significant level of unsaturated product. Incubation of the unsaturated product and fluoride with active enzyme did not result in the formation of substrate, showing that the elimination reaction was irreversible. Steady-state kinetic analysis of the reaction shows that elimination of this substrate is ca. 32 x more efficient than chiral inversion of S-2-methyldecanoyl-CoA, as judged by $k_{cat}/K_m$. This new reaction has potential uses for the development of a high-throughput assay for development of AMACR inhibitors. It may also all development of more convenient techniques for diagnosing and monitoring prostate cancer based on AMACR activity.